• 尊龙凯时

    SynRx
    SynRx
    SynRx
    SynRx SynRx
    To deliver the first-in-class medicines to cancer patients
    Company Development Vision Advantage Leadership Partnerships
    Company
    To deliver the first-in-class medicines to cancer patients
    SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in-class anti-tumor compounds, and preclinical studies are in progress .
    SynRx
    SynRx
    SynRx
    Development strategy
    Using synthetic lethality strategies, we are developing the first-in-class anti-cancer agents.
    SynRx
    SynRx
    SynRx
    SynRx
    Aug.
    SynRx Therapeutics was founded
    2021
    Jan.
    The biology research and development center was established
    2022
    Mar.
    Inauguration of the Shanghai Branch
    2022
    The Vision
    Targeting DNA damage repair pathway to develop anti-cancer agents
    Advantage
    SynRx
    • SynRx SynRx
      Synthetic lethality strategy
      Synthetic lethality strategy allows us to cure cancers with mutations on tumor suppressor genes. In particular, we are able to indirectly target those “undruggable” tumor suppressors to drastically expand the scope of cancer therapeutics. In combination with other types of cancer therapies, such as tumor immunotherapy, our approach also has the potential to overcome cancer drug resistance caused by secondary mutations arising from conventional cancer therapies. In short, synthetic lethality strategies specifically kill cancer cells with a clear biomarker and create a clear pathway for cancer treatment.
    • SynRx SynRx
      Focusing on DNA damage repair pathways
      Genomic instability is a hallmark of tumor cells and is often caused by DNA damage repair defects. To make use of this weakness, we are developing novel approaches to not only selectively kill tumor cells but also leave normal cells unharmed. Thus, our goal is to obtain maximal therapeutic window with little side-effect.
    • SynRx SynRx
      Leading the development of original targets
      Original research conducted in Dr./Professor Yu’s lab has opened a new field of DNA damage repair has helped build the foundation of the company's "source of innovation" on drug development. We continue to collaborate with well recognized leaders in academia and industry to conduct cutting-edge research.
    Leadership
    SynRx
    Xiaochun Yu Professor
    Founder and Chairman

    Professor and Associate Dean, School of Life Sciences, Westlake University

    Professor, University of Michigan Medical School

    M.D., Beijing Medical University; Ph.D, Kurume University, Japan

    Published more than 100 academic papers

    SynRx
    Song Liu PhD
    Co-founder and CEO

    Executive director of a well-known healthcare professional investment fund, invests and manages more than 20 biotechnology companies, many of which have successfully listed in Hong Kong and the US stock markets or completed mergers and acquisitions

    Investigator of Medicinal Chemistry, Novartis Institutes of Biomedical Research, small molecule research and development on epigenetics

    PhD in chemistry, University of Chicago

    Partnerships
    We are looking for partners and collaborators on the development of anti-tumor therapies.
    SynRx
    Business Development bd@mini818.com
    Careers hr@mini818.com
    Address @ Room 201, Building 4, 1390 Cangxing Street, Cangqian Subdistrict, Yuhang District, Hangzhou, Zhejiang @ Room 303, No.1, Lane 88, Shengrong Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai
    CopyRight 2022 All Right Reserved SynRx Therapeutics 浙ICP备2021033925号 SiteMap
    SynRx
    SynRx
    SynRx
    0571-86360796
    SynRx
    SynRx
    杭氧
    Name
    Position
    Introduce